| Literature DB >> 12724731 |
Daniel B Longley1, D Paul Harkin, Patrick G Johnston.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12724731 DOI: 10.1038/nrc1074
Source DB: PubMed Journal: Nat Rev Cancer ISSN: 1474-175X Impact factor: 60.716